Tekla Capital Management LLC Cerevel Therapeutics Holdings, Inc. Transaction History
Tekla Capital Management LLC
- $2.53 Billion
- Q2 2023
A detailed history of Tekla Capital Management LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 176,483 shares of CERE stock, worth $0. This represents 0.22% of its overall portfolio holdings.
Number of Shares
176,483
Previous 176,483
-0.0%
Holding current value
$0
Previous $4.3 Million
30.34%
% of portfolio
0.22%
Previous 0.17%
Shares
4 transactions
Others Institutions Holding CERE
# of Institutions
21Shares Held
5.93MCall Options Held
27.3KPut Options Held
0-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Segantii Capital Management LTD1.14MShares$05.99% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA393KShares$00.95% of portfolio
-
Jane Street Group, LLC New York, NY270KShares$00.01% of portfolio
-
Credit Suisse Ag Zurich, V8112KShares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...